PET imaging test to plan personalized prostate cancer treatment
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and under 75 (different groups use different age limits)
- You have confirmed prostate cancer from a biopsy (proven by pathology)
- You must be scheduled for radical prostatectomy with extended lymph node removal (for the surgery group)
- For the relapse group: your PSA has risen twice after prior prostate treatment, and you can do study visits (WHO performance 0–1)
- You must not have signs of pelvic lymph node involvement on MRI (for the surgery group) or bone spread on scan (if PSA is high)
- You must not have certain hormone/medication issues, recent PSA-altering drugs, or difficulty understanding consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This study uses two different PSMA PET/CT tracers to see how well they detect cancer in patients with advanced prostate cancer that has spread or stopped responding to hormone therapy. The goal is to improve imaging for better treatment decisions.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This trial tests a new radioactive tracer called ELI421 to see how well it works for PET imaging in people with prostate cancer. It may help doctors find cancer more clearly.
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.